Deletion of the Williams Beuren syndrome critical region unmasks facioscapulohumeral muscular dystrophy by Rodolico, C. et al.
lable at ScienceDirect
European Journal of Paediatric Neurology 27 (2020) 25e29Contents lists avaiEuropean Journal of Paediatric NeurologyDeletion of the Williams Beuren syndrome critical region unmasks
facioscapulohumeral muscular dystrophy
Carmelo Rodolico a, 1, Luisa Politano b, 1, Simona Portaro c, Stefania Murru d,
Loredana Boccone d, Francesco Sera e, Luigia Passamano b, Teresa Brizzi a, f,
Rossella Tupler g, h, *
a Department of Clinical and Experimental Medicine, University of Messina, Italy
b Cardiomyology and Medical Genetics, Department of Experimental Medicine, University of Campania, “Luigi Vanvitelli”, Naples, Italy
c IRCCS Centro Neurolesi Bonino Pulejo, Messina, Italy
d Azienda Ospedaliera “G.Brotzu”, Cagliari, Italy
e Department of Public Health, Environments and Society, London School of Hygiene and Tropical Medicine, London, UK
f "Piemonte” Hospital, Messina, Italy
g Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy
h Department of of Molecular, Cell and Cancer Biology, University of Massachsetts Medical School, Worcester, USAa r t i c l e i n f o
Article history:
Received 31 October 2019
Received in revised form
10 May 2020
Accepted 15 May 2020* Corresponding author. Department of Biomedical
E-mail address: rossella.tupler@unimore.it (R. Tup
1 These authors contributed equally to the work.
https://doi.org/10.1016/j.ejpn.2020.05.006
1090-3798/© 2020 The Authors. Published by Elsevier
(http://creativecommons.org/licenses/by-nc-nd/4.0/).a b s t r a c t
Among 1339 unrelated cases accrued by the Italian National Registry for facioscapulohumeral muscular
dystrophy (FSHD), we found three unrelated cases who presented signs of Williams-Beuren Syndrome
(WBS) in early childhood and later developed FSHD. All three cases carry the molecular defects associ-
ated with the two disorders. The rarity of WBS and FSHD, 1 in 7500 and 1 in 20,000 respectively, makes a
random association of the two diseases unlikely. These cases open novel and unexpected interpretation
of genetic findings. The nonrandom association of both FSHD and WBS points at a gene co-expression
network providing hints for the identification of modules and functionally enriched pathways in the
two conditions.
© 2020 The Authors. Published by Elsevier Ltd on behalf of European Paediatric Neurology Society. This is
an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.
0/).1. Introduction
Deletion of an integral number of 3.3 Kb tandemly arrayed re-
peats, named D4Z4, at the subtelomeric region of chromosome 4,
4q35, is considered the hallmark of facioscapulohumeral muscular
dystrophy (FSHD; OMIM 158900) [1]. Although themajority of FSHD
affected people carry one D4Z4 allelewith 10 or fewer repeats, in the
general population there is 3% of healthy individuals carrying D4Z4
allele of the same size [2]. Thus a large number of potentially pre-
disposed people do not develop disease and incidentally discovered
carriers of D4Z4 reduced alleles do not report FSHD cases in their
families. Reduced penetrance of this molecular defect is also
observed in FSHD families [3,4]. There are also scattered reports of
patients presenting complex clinical phenotypes, some showing, Metabolic and Neural Sciences, U
ler).
Ltd on behalf of European Paediatatypical distribution of muscle weakness or atypical presentation of
disease onset or progression, some presenting extra-muscular fea-
tures such as hearing loss, retinal vascular disease, respiratory
insufficiency, cognitive impairment or epilepsy [5]. In some cases the
atypical features have been attributed to mutations in other
genes [6]. All these observations indicate that the wide phenotypic
spectrum observed in individuals carrying D4Z4 reduced alleles is
determined by the genetic background and, possibly, by environ-
mental factors. We thus reasoned that families including healthy
carriers as well as subjects with atypical features might facilitate the
identification of genetic components that contribute or interfere
with the clinical phenotype.
We screened the Italian National Registry for FSHD (INRF) for
cases with complex phenotypes in families with reducedniversity of Modena and Reggio Emilia, via G. Campi 287, Modena, 41125, Italy.
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Fig. 1. Representative photographs and pedegrees from subjects with concomitant facioscapulohumeral muscular dystrophy and Williams-Beuren Syndrome. Photographs
of Case 1 obtained at 14 years show pouty lips, sloping shoulders and straight clavicle (A) and winging and asymmetric shoulders, scoliosis (B). Family Pedegree of Case 1 (C).
Photographs of case 2 obtained at 12 years show lumbar hyperlordosis (D); asymmetric scapular winging with periscapular hypotrophy and limited abduction (E). Family Pedegree
of Case 2 (panel F). Photographs of case 3: at the age of 2 years the patients shows full cheeks and pouty lips (G); at the age of 10 he displays years straight clavicles, axillary plicae
and bilateral elevation of trapezius muscle are evident (H), at the age of 29 years he has severe lumbar hyperlordosis (I) and marked difficulty in raising arms with polyhill sign
(panel J). Family pedigree of Case 3 (panel K). RU, Repeat Units.
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relatives from the INRF, all carrying at least one D4Z4 deleted allele
we found three cases presenting both FSHD and Williams-Beuren
syndrome (WBS; OMIM 194050) due to the typical 7q11.23
deletion.2. Methods
2.1. Genetic studies
We performed standard molecular diagnostic procedures for
WBS and FSHD. Our institutional ethics committee approved the
Table 1
Synopsis of overlapping clinical features in FSHD and WBS.
Clinical feature FSHD WBS
musculoskeletal weakness (muscle hypotonia) þþþþ þþ
Myopathy þþþþ þþ
down sloping shoulder þþþ þþþ
Hyperlordosis þþþ þþ
Scoliosis þþ þþ
Pectus excavatum þþþ þþ
elevated serum creatine phosphokinase þþþ þþ
global cognitive impairment þ þþþþ
mild-to-moderate high-tone sensorineural hearing loss þþ þþ
narrow face þ þþþþ
hypoplasia of the zygomatic bone þ þþþ
malar flattening þ þþ
Micrognatia þ þþþþ
thick lower lip vermilion þþ þþþþ
Dysarthria þ þ
joint contraction (adult) þ þ
List of selected symptoms described in WBS cases from the Human Phenotype
Ontology (HPO) database. Frequency of symptoms are detailed as follows: þþþþ
80%e99% of people have these symptoms; þþþ 30%e79% of people have these
symptoms; þþ 5%e29% of people have these symptoms; þ sporadically observed.
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parents in accordance with the ethical standards of the 1964
Declaration of Helsinki.3. Results
3.1. Case 1
At the age of 3 years because of aortic and pulmonary valve
stenosis, hypotonia, delayed developmental milestones and typical
facial features the patient was investigated for suspected Williams-
Beuren Syndrome (WBS). Molecular diagnosis revealed the typical
1.55 Mb deletion on chromosome 7q11.23. At 11 years he had dif-
ficulty in raising arms and underwent surgical scapular fixation,
without beneficial effect. At the age of 14 years he presented thick
lower lip vermilion, sloping shoulders, straight clavicles, bilateral
scapular winging asymmetric shoulders and scoliosis (Fig. 1A and
B), hypotrophy of periscapular muscles with difficulties in raising
arms above shoulders, hypotrophy of pectoralis and triceps muscles
and quadriceps muscles. Neuromuscular examination disclosed
orbicularis oculis and oris muscle weakness, waddling gait with
bilateral “steppage”, lumbar hyperlordosis, weakness of neck
flexors, pectoralis, triceps and wrist extensors muscles; at lower
limbs weakness of iliopsoas, quadriceps and tibialis anterior muscle
was detected. Deep tendon reflexes were weak at the upper limbs.
He had a moderate intellectual deficit (IQ 46) with impaired vi-
suospatial skills and social disinhibition; EEG and brain MRI
showed no abnormalities. Echocardiography confirmed the pres-
ence of aortic and pulmonary valve stenosis; a depression of the ST
segment and the T wave inversion were evident at ECG. Serum
Creatine Kinase (CK) was slightly increased (401 U/L). Electromy-
ography showedmyopathic pattern. Molecular testing revealed one
D4Z4 allele with 4 Repeat Units (RU) on chromosome 4q35, sup-
porting the diagnosis of FSHD. The healthy father carries the same
reduced D4Z4 allele (Fig. 1C).3.2. Case 2
At the age of 16 months, because of craniofacial dysmorphisms
(esotropia, periorbital puffiness, short nose, full cheeks, thick lower
lip vermilion, small chin and bilateral temporal narrowing),
delayed motor skills with difficulty in walking and standing up,with muscle weakness, the finding of depression of the ST segment
at ECG and aortic valve stenosis at echocardiography, the patient
was investigated for suspected WBS. Molecular diagnosis revealed
a 1.55 Mb deletion at 7q11.23, consistent with WBS diagnosis.
Walking was achieved at 17 months; at the same age a moderate
increase of CK was detected (300e400 UI/L). At 12 years of age, he
presented scapular winging and asymmetric shoulders, wasting of
the pectoral and upper limb muscles, bilateral axillary plicae,
inability to raise arms above 45, dorsal scoliosis, lumbar hyper-
lordosis, thick lower lip vermilion and lagophthalmos evocating
FSHD (Fig. 1D and E). He had a moderate intellectual deficit (IQ 48),
whereas EEG and brain MRI did not reveal significant abnormal-
ities. Molecular analysis showed one D4Z4 allele with 6 RU. The
same allele was detected in his mother, to date totally asymptom-
atic (Fig. 1F).
3.3. Case 3
At 11 months of age because of motor skill delay, typical facial
dysmorphisms (Fig. 1G), aortic and pulmonary valve stenosis, joint
hypermobility and fair chest the patient was investigated for sus-
pected WBS. Molecular analysis showed a 1.55 Mb deletion on
chromosome 7q11.23. At the age of 10 years he showed asymmetric
facial weakness, and moderate muscle weakness, more evident at
shoulder girdle, with straight clavicles and axillary fold (Fig. 1H). At
this age amoderate intellectual deficit was also evident: I.Q. was 49,
with significant discrepancy between the higher level verbal tests
(I.Q. 59) and the other performances (I.Q. 42). EEG was normal,
brain MRI was not performed. A depression of the ST segment with
T wave inversionwere present at ECG. Muscular features worsened
through time and, at age 29 years, he has a clear myopathy with
facial involvement, severed lumbar hyperlordosis and prevalent
upper limbs wasting and weakness with difficulty in raising the
arms (Fig. 1I and J). CK levels were normal. Molecular testing for
FSHD revealed one D4Z4 allele with 9 RU. Several asymptomatic
relatives (I.2, II.1, II.5, II.8, II.14, II.17, III.9, III.16, III.17) carry the same
D4Z4 allele with 9 RU as shown in Fig. 1K.
4. Discussion
WBS and FSHD are two rare autosomal dominant disorders,
with an estimated prevalence of 1 in 7,500, and 1 in 20,000 in-
dividuals respectively [7,8]. Both syndromes are clinically recog-
nizable and distinguishable: WBS patients present with a
combination of specific cardiovascular disease (specifically elastin
arteriopathy, peripheral pulmonary stenosis, supravalvular aortic
stenosis and hypertension), typical facial features, connective tissue
abnormalities, intellectual disability, a specific cognitive profile,
unique personality characteristics, growth abnormalities, muscu-
loskeletal abnormalities and endocrine abnormalities [9]. FSHD
patients manifest a selective progressive weakness of the facial and
scapular girdle muscles with subsequent involvement of the foot
dorsiflexors and pelvic girdle muscles [10]. In both WBS and FSHD,
wide spectra of phenotypes are observed in association with the
molecular defects characteristic of each disease. We describe and
discuss some similarities about these two syndromes and we
consider the clinical clues for the diagnosis and future perspectives.
Our findings of three cases carrying the hallmark mutations of
both FSHD andWBS suggest that there is a non-random association
between the two different chromosomal loci. Indeed among 1339
unrelated FSHD index cases carrying D4Z4 reduced alleles accrued
in the INRF the prevalence of WBS was 22.4 (4.6e65.5) in 10,000.
This value is significantly higher (Poisson exact test p
value ¼ 0.0008) than the expected (1 in 7500) or (1.3 in 10,000),
suggesting that they result from a synergistic mechanism. In each
Fig. 2. Schematic representation of the Williams-Beuren Chromosome region. (A) The WilliamseBeuren syndrome is characterized by interstitial deletion of 1.55e1.8 Mb on
chromosome 7, at 7q11.23. An enlarged view of the Williams-Beuren Syndrome Chromosome Region (WBSCR) includes genes within the region and their expression profile in
multiple tissues obtained by next-generation sequencing technologies (RNA-seq) as reported in the GTEX RNAseq database. (B) Transcription levels of the WBSCR genes in Central
Nervous System (CNS), Skeletal Muscle (SkMu) and TibialisNerve (TibNe) are detailed as follows: þ 10 RPKM; þþ >10e20 RPKM; þþþ >20  100; þþþþ100; - no expression;
NE Not Evaluated. RPKM, Reads Per Kilobase of transcriptper Million mapped reads.
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the WBS chromosome region deletion not only determines the
presence of clinical features of WBS, but it appears to contribute to
the development of muscle weakness typical of FSHD in a carrier of
a D4Z4 deleted allele. In fact all probands developed very severe
muscle impairment at a young age, whereas their relatives carrying
the same reduced D4Z4 allele are asymptomatic at adult age. These
findings are consistent with data pointing at the possibility that, in
the heterozygous state, a D4Z4 contraction might produce a sub-
clinical condition that requires other genetic or epigenetic mech-
anisms or contributing factors to cause an overt myopathy [2].
Another hint for a possible direct interaction of the two muta-
tions on the phenotype comes from some similarities between
these two syndromes as summarized in Table 1 A “myopathic
picture” (not dystrophic) has been frequently described as part of
the spectrum of WBS [11]. In particular, dysmorphic facial features,
such as thick lower lip vermilion, horizontal smile, weak orbicularis
oculi muscles, and anomalies in the spine curvature, indicating thepresence of muscle weakness, are observed in WBS [12]. Moreover
some FSHD subjects present extra-muscular involvement such as
retinal vascular disease, high-tone hearing loss, cognitive impair-
ment and epilepsy [5]. Additionally, in the group of patients car-
rying D4Z4 alleles with 1e3 repeats, we observed cognitive
impairment in 35% of FSHD cases presenting extra-muscular
comorbidities [5].
The 1.8 Mb WBS chromosome region
(chr7:73,150,048e74,950,182) contains 28 genes, reported in Fig. 2B.
Thirteen of them are expressed in skeletal muscle, central nervous
system and tibialis nerve (as reported by the GTEX RNAseq database).
Among these genes, ELN, which encodes elastin, is the only gene
with a definite effect in WBS. Its haploinsufficiency accounts for
arteriopathy and heterozygous mutations in ELN have been associ-
ated with autosomal dominant cutis laxa (OMIM 123700) and
supravalvular aortic stenosis (OMIM 185700). Interestingly its
expression was found specifically reduced in FSHD myoblasts, sug-
gesting a possible involvement of elastin in FSHD cellular
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mechanism of genes mapping to the WBS chromosome region re-
mains to be elucidated [13].
Do genes located within WBS chromosome region or D4Z4
deleted alleles act as modifiers of the FSHD or WBS phenotypes?
Which traces should we follow? FSHD cases showing atypical
clinical features, including mental disability, arterial stenosis,
should be considered for further molecular investigations. We also
suggest to suspect the presence of one D4Z4 reduced allele in WBS
patients, when there is a prominent involvement of shoulder girdle
with winging scapulae, peroneal muscle weakness, increased CK
levels, marked hyperlordosis, even if facial muscles seems to be
spared, in the context of the typical appearance of WBS face.
These three cases with the co-presence of the molecular defects
associate with two rare diseases WBS and FSHD provide concrete
evidences of themolecular interactions thatmight underlie the two
diseases. From a molecular point of view, several observations
indicate that the spectrum of clinical variations inWBS is controlled
by multiple genes. Genotype-phenotype studies on WBS suggest
that the telomeric part of the WBSCR has a relevant role in the
clinical presentation of the syndrome, but no definite gene has been
identified [14]. In the field of FSHD there are accumulating evi-
dences that the reduction of D4Z4 repetitive elements is not per se
sufficient to cause disease [2]. It is also definite that multiple phe-
notypes can be found in people carrying the same molecular
markers including healthy people or subjects with other
diseases [6,15].
This nonrandom association of both FSHD and WBS reveals a
gene co-expression network that provides hints for identifying
modules and functionally enriched pathways at the basis of the
patients’ phenotypes. For instance, mice deficient in EIF4H, an
important factor for the initiation of translation, are small with
reduced endurance to fatigue [16]. FZD9 is expressed in developing
skeletal muscles during NMJ synaptogenesis an its differential
expression influences AChR clustering [17]. MLXIPL is a glucose-
responsive transcription factor, which increases its activity in
response to changes in glucose levels and promotes myogenesis by
inducing the expression of several myokines [18]. In addition
GTF2IRD1 may play an important role in fiber-specific muscle gene
expression at early stages of muscle development [19].
The cases described here highlight the possibility that several
genes, deleted in WBS, could operate on the same molecular
network compromised in FSHD, acting as modifier genes. Indeed,
the use of massive parallel sequencing for diagnostic purposes has
revealed more than one mutation or copy number variations in
individuals with a rare disease. This finding has been interpreted as
the co-occurrence of independent mutations [20]. However these
findings pose particular challenges for clinical practice, including
diagnosis, prognosis, genetic counseling and design of clinical trials.
Here we show that a thorough clinical work, including systematic
detailed description of phenotypes can open novel and unexpected
interpretation of genetic findings. This approach centered on the
phenotype analysis has the potential of shedding new light on the
complex molecular interactions whose alteration leads to rare
diseases and their clinical expression.
Author contributions
CR and RT planned, supervised the study, and wrote the
manuscript. LPo provided clinical data and contributed to the
writing of the manuscript. SP, LB, TB, LPa provided clinical data andcollected the consent forms. TB undertook the data extraction and
contributed to the writing of the manuscript. FS performed statis-
tical analysis. SM performed molecular analysis and contributed to
the writing of the manuscript.
Declaration of competing interest
The authors declare that they have no known competing
financial interests or personal relationships that could have
appeared to influence the work reported in this paper.
Acknowledgements
We are indebted to all patients and their families for partici-
pating in this study.
This work was supported by Telethon, Italy GUP13012, by
Regione Emilia Romagna, Italy.
References
[1] P.W. Lunt, P.S. Harper, Genetic counselling in facioscapulohumeral muscular
dystrophy, J. Med. Genet. 10 (1991) 655e664.
[2] I. Scionti, F. Greco, G. Ricci, et al., Large scale population analysis challenges
the current criteria for the molecular diagnosis of fascioscapulohumeral
muscular dystrophy (FSHD), Am. J. Hum. Genet. 90 (2012) 628e635.
[3] K. Goto, I. Nishino, Y.K. Hayashi, Very low penetrance in 85 Japanese families
with facioscapulohumeral muscular dystrophy 1A, J. Med. Genet. 41 (2004)
e12.
[4] G. Ricci, I. Scionti, F. Sera, et al., Large-scale genotype-phenotype analyses
indicate that novel prognostic tools are required for facioscapulohumeral
muscular dystrophy families, Brain 136 (2013) 3408e3417.
[5] A. Nikolic, G. Ricci, F. Sera, et al., Clinical expression of facioscapulohumeral
muscular dystrophy in carriers of 1-3 D4Z4 reduced alleles: experience of the
FSHD Italian National Registry, BMJ 6 (2016), e007798.
[6] G. Ricci, M. Zatz, R. Tupler, Facioscapulohumeral muscular dystrophy: more
complex than it appears, Curr. Mol. Med. 14 (2014) 1052e1068.
[7] P. Strømme, P.G. Bjørnstad, K. Ramstad, Prevalence estimation of Williams
syndrome, J. Child Neurol. 17 (2002) 269e271.
[8] M.L. Mostacciuolo, E. Pastorello, G. Vazza, et al., Facioscapulohumeral
muscular dystrophy: epidemiological and molecular study in a northeast
Italian population sample, Clin. Genet. 75 (2009) 550e555.
[9] B.R. Pober, Williams-Beuren syndrome, N. Engl. J. Med. 362 (2010) 239e252.
[10] G.W. Padberg, P.W. Lunt, M. Koch, M. Fardeau, Diagnostic criteria for facio-
scapulohumeral muscular dystrophy, Neuromuscul. Disord. 1 (1991)
231e234.
[11] L.E. Copes, B.R. Pober, C.A. Terilli, Description of common musculoskeletal
findings in Williams Syndrome and implications for therapies, Clin. Anat. 29
(2016) 578e589.
[12] S.T. Winokur, K. Barrett, J.H. Martin, et al., Facioscapulohumeral muscular
dystrophy (FSHD) myoblasts demonstrate increased susceptibility to oxida-
tive stress, Neuromuscul. Disord. 13 (2003) 322e333.
[13] C.A. Morris, S.A. Demsey, C.O. Leonard, et al., Natural history of Williams
syndrome: physical characteristics, J. Pediatr. 113 (1988) 318e326.
[14] J. Euteneuer, C.M. Carvalho, S. Kulkarni, et al., Molecular and phenotypic
characterization of atypical Williams-Beuren syndrome, Clin. Genet. 86 (2014)
487e491.
[15] L. Ruggiero, F. Mele, F. Manganelli, et al., Phenotypic variability among Pa-
tients with D4Z4 reduced allele Facioscapulohumeral muscular dystrophy,
JAMA Open Netw. 3 (2020 May 1), e204040.
[16] S. Capossela, L. Muzio, A. Bertolo, et al., Growth defects and impaired
cognitive-behavioral abilities in mice with knockout for Eif4h, a gene located
in the mouse homolog of the Williams-Beuren syndrome critical region, Am. J.
Pathol. 180 (2012) 1121e1135.
[17] E.C. Aviles, C. Pinto, P. Hanna, et al., Frizzled-9 impairs acetylcholine receptor
clustering in skeletal muscle cells, Front. Cell. Neurosci. 8 (2014) 110.
[18] L.C. Hunt, B. Xu, D. Finkelstein, Y. Fan, et al., The glucose-sensing transcription
factor MLX promotes myogenesis via myokine signaling, Genes Dev. 29 (2015)
2475e2489.
[19] E.S. Tay, K.L. Guven, N. Subramaniam, et al., Regulation of alternative splicing
of Gtf2ird1 and its impact on slow muscle promoter activity, Biochem. J. 374
(2003) 359e367.
[20] J.E. Posey, T. Harel, P. Liu, et al., Resolution of disease phenotypes resulting
from multilocus genomic variation, N. Engl. J. Med. 376 (2017) 21e31.
